The CRM1 nuclear export protein in normal development and disease

International Journal of Biochemistry and Molecular Biology

Volumn 3, Issue 2, 2012, Pages 137-151

  Nguyen, Kevin T ^a   Holloway, Michael P ^a   Altura, Rachel A ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

APC; BRCA1; CRM1; Leptomycin B; NPM; Nuclear pore complex; p27; p53; Survivin

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EXPORTIN 1; LEPTOMYCIN B; NUCLEOPHOSMIN; PROTEIN P53; SURVIVIN; TUMOR SUPPRESSOR PROTEIN;

CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL TRANSPORT; CENTROSOME; CHROMATIN ASSEMBLY AND DISASSEMBLY; CRM1 GENE; CRYSTAL STRUCTURE; CYTOSOLIC FRACTION; DEVELOPMENT; DISEASE COURSE; DNA DAMAGE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE; HUMAN; LARVAL DEVELOPMENT; MITOSIS SPINDLE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINASE INHIBITION; REVIEW; SPINDLE CELL; TRANSCRIPTION REGULATION;

EID: 84862501107     PISSN: None     EISSN: 21524114     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. Gorlich D and Mattaj IW. Nucleocytoplasmic transport. Science 1996; 271: 1513-1518.
2. Pante N and Aebi U. Toward the molecular details of the nuclear pore complex. J Struct Biol 1994; 113: 179-189.
3. Simos G and Hurt EC. Nucleocytoplasmic transport: factors and mechanisms. FEBS Lett 1995; 369: 107-112.
4. Rout MP and Wente SR. Pores for thought: nuclear pore complex proteins. Trends Cell Biol 1994; 4: 357-365.
5. Goldberg MW and Allen TD. Structural and functional organization of the nuclear envelope. Curr Opin Cell Biol 1995; 7: 301-309.
6. Doye V and Hurt E. From nucleoporins to nuclear pore complexes. Curr Opin Cell Biol 1997; 9: 401-411.
7. Davis LI. The nuclear pore complex. Annu Rev Biochem 1995; 64: 865-896.
8. Chadrin A, Hess B, San Roman M, Gatti X, Lombard B, Loew D, Barral Y, Palancade B and Doye V. Pom33, a novel transmembrane nucleoporin required for proper nuclear pore complex distribution. J Cell Biol 2010; 189: 795-811.
9. Gerace L, Ottaviano Y and Kondor-Koch C. Identification of a major polypeptide of the nuclear pore complex. J Cell Biol 1982; 95: 826-837.
10. Hallberg E, Wozniak RW and Blobel G. An integral membrane protein of the pore membrane domain of the nuclear envelope contains a nucleoporin-like region. J Cell Biol 1993; 122: 513-521.
11. Mansfeld J, Guttinger S, Hawryluk-Gara LA, Pante N, Mall M, Galy V, Haselmann U, Muhlhausser P, Wozniak RW, Mattaj IW, Kutay U and Antonin W. The conserved transmembrane nucleoporin NDC1 is required for nuclear pore complex assembly in vertebrate cells. Mol Cell 2006; 22: 93-103.
12. Stavru F, Hulsmann BB, Spang A, Hartmann E, Cordes VC and Gorlich D. NDC1: a crucial membrane- integral nucleoporin of metazoan nuclear pore complexes. J Cell Biol 2006; 173: 509-519.
13. Terry LJ and Wente SR. Flexible gates: dynamic topologies and functions for FG nucleoporins in nucleocytoplasmic transport. Eukaryot Cell 2009; 8: 1814-1827.
14. Walde S and Kehlenbach RH. The Part and the Whole: functions of nucleoporins in nucleocytoplasmic transport. Trends Cell Biol 2010; 20: 461-469.
15. Wente SR and Rout MP. The nuclear pore complex and nuclear transport. Cold Spring Harb Perspect Biol 2010; 2: a000562.
16. Nigg EA. Nucleocytoplasmic transport: signals, mechanisms and regulation. Nature 1997; 386: 779-787.
17. Izaurralde E, Lewis J, Gamberi C, Jarmolowski A, McGuigan C and Mattaj IW. A cap-binding protein complex mediating U snRNA export. Nature 1995; 376: 709-712.
18. Mattaj IW and Englmeier L. Nucleocytoplasmic transport: the soluble phase. Annu Rev Biochem 1998; 67: 265-306.
19. Fried H and Kutay U. Nucleocytoplasmic transport: taking an inventory. Cell Mol Life Sci 2003; 60: 1659-1688.
20. Gerace L. Nuclear export signals and the fast track to the cytoplasm. Cell 1995; 82: 341-344.
21. Fornerod M, Ohno M, Yoshida M and Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997; 90: 1051- 1060.
22. Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M and Nishida E. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997; 390: 308-311.
23. Stade K, Ford CS, Guthrie C and Weis K. Exportin 1 (Crm1p) is an essential nuclear export factor. Cell 1997; 90: 1041-1050.
24. Melchior F and Gerace L. Two-way trafficking with Ran. Trends Cell Biol 1998; 8: 175-179.
25. Moore MS. Ran and nuclear transport. J Biol Chem 1998; 273: 22857-22860.
26. Wozniak RW, Rout MP and Aitchison JD. Karyopherins and kissing cousins. Trends Cell Biol 1998; 8: 184-188.
27. Rexach M and Blobel G. Protein import into nuclei: association and dissociation reactions involving transport substrate, transport factors, and nucleoporins. Cell 1995; 83: 683-692.
28. Izaurralde E, Kutay U, von Kobbe C, Mattaj IW and Gorlich D. The asymmetric distribution of the constituents of the Ran system is essential for transport into and out of the nucleus. EMBO J 1997; 16: 6535-6547.
29. Kutay U, Bischoff FR, Kostka S, Kraft R and Gorlich D. Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor. Cell 1997; 90: 1061-1071.
30. Kutay U, Izaurralde E, Bischoff FR, Mattaj IW and Gorlich D. Dominant-negative mutants of importin-beta block multiple pathways of import and export through the nuclear pore complex. EMBO J 1997; 16: 1153-1163.
31. Arts GJ, Kuersten S, Romby P, Ehresmann B and Mattaj IW. The role of exportin-t in selective nuclear export of mature tRNAs. EMBO J 1998; 17: 7430-7441.
32. Coutavas E, Ren M, Oppenheim JD, D'Eustachio P and Rush MG. Characterization of proteins that interact with the cell-cycle regulatory protein Ran/TC4. Nature 1993; 366: 585-587.
33. Bischoff FR, Krebber H, Smirnova E, Dong W and Ponstingl H. Co-activation of RanGTPase and inhibition of GTP dissociation by Ran-GTP binding protein RanBP1. EMBO J 1995; 14: 705-715.
34. Ohtsubo M, Okazaki H and Nishimoto T. The RCC1 protein, a regulator for the onset of chromosome condensation locates in the nucleus and binds to DNA. J Cell Biol 1989; 109: 1389-1397.
35. Adachi Y and Yanagida M. Higher order chromosome structure is affected by cold-sensitive mutations in a Schizosaccharomyces pombe gene crm1+ which encodes a 115-kD protein preferentially localized in the nucleus and its periphery. J Cell Biol 1989; 108: 1195-1207.
36. Toda T, Shimanuki M, Saka Y, Yamano H, Adachi Y, Shirakawa M, Kyogoku Y and Yanagida M. Fission yeast pap1-dependent transcription is negatively regulated by an essential nuclear protein, crm1. Mol Cell Biol 1992; 12: 5474-5484.
37. Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S and Beppu T. Leptomycin B targets a regulatory cascade of crm1, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J Biol Chem 1994; 269: 6320-6324.
38. Turi TG, Webster P and Rose JK. Brefeldin A sensitivity and resistance in Schizosaccharomyces pombe. Isolation of multiple genes conferring resistance. J Biol Chem 1994; 269:24229-24236.
39. Kumada K, Yanagida M and Toda T. Caffeineresistance in fission yeast is caused by mutations in a single essential gene, crm1+. Mol Gen Genet 1996; 250: 59-68.
40. Toone WM, Kuge S, Samuels M, Morgan BA, Toda T and Jones N. Regulation of the fission yeast transcription factor Pap1 by oxidative stress: requirement for the nuclear export factor Crm1 (Exportin) and the stress-activated MAP kinase Sty1/Spc1. Genes Dev 1998; 12: 1453-1463.
41. Fornerod M, van Baal S, Valentine V, Shapiro DN and Grosveld G. Chromosomal localization of genes encoding CAN/Nup214-interacting proteins--human CRM1 localizes to 2p16, whereas Nup88 localizes to 17p13 and is physically linked to SF2p32. Genomics 1997; 42: 538-540.
42. Fornerod M, van Deursen J, van Baal S, Reynolds A, Davis D, Murti KG, Fransen J and Grosveld G. The human homologue of yeast CRM1 is in a dynamic subcomplex with CAN/Nup214 and a novel nuclear pore component Nup88. EMBO J 1997; 16: 807-816.
43. Askjaer P, Jensen TH, Nilsson J, Englmeier L and Kjems J. The specificity of the CRM1-Rev nuclear export signal interaction is mediated by RanGTP. J Biol Chem 1998; 273: 33414-33422.
44. Neville M, Stutz F, Lee L, Davis LI and Rosbash M. The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export. Curr Biol 1997; 7: 767-775.
45. Pollard VW and Malim MH. The HIV-1 Rev protein. Annu Rev Microbiol 1998; 52: 491-532.
46. Fischer U, Huber J, Boelens WC, Mattaj IW and Luhrmann R. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 1995; 82: 475-483.
47. Wen W, Meinkoth JL, Tsien RY and Taylor SS. Identification of a signal for rapid export of proteins from the nucleus. Cell 1995; 82: 463-473.
48. Huber J, Cronshagen U, Kadokura M, Marshallsay C, Wada T, Sekine M and Luhrmann R. Snurportin1, an m3G-cap-specific nuclear import receptor with a novel domain structure. EMBO J 1998; 17: 4114-4126.
49. Paraskeva E, Izaurralde E, Bischoff FR, Huber J, Kutay U, Hartmann E, Luhrmann R and Gorlich D. CRM1-mediated recycling of snurportin 1 to the cytoplasm. J Cell Biol 1999; 145: 255-264.
50. Monecke T, Guttler T, Neumann P, Dickmanns A, Gorlich D and Ficner R. Crystal structure of the nuclear export receptor CRM1 in complex with Snurportin1 and RanGTP. Science 2009; 324: 1087-1091.
51. Dong X, Biswas A, Suel KE, Jackson LK, Martinez R, Gu H and Chook YM. Structural basis for leucine-rich nuclear export signal recognition by CRM1. Nature 2009; 458: 1136-1141.
52. Wohlwend D, Strasser A, Dickmanns A and Ficner R. Structural basis for RanGTP independent entry of spliceosomal U snRNPs into the nucleus. J Mol Biol 2007; 374: 1129-1138.
53. Mitrousis G, Olia AS, Walker-Kopp N and Cingolani G. Molecular basis for the recognition of snurportin 1 by importin beta. J Biol Chem 2008; 283: 7877-7884.
54. Gorlich D, Pante N, Kutay U, Aebi U and Bischoff FR. Identification of different roles for RanGDP and RanGTP in nuclear protein import. EMBO J 1996; 15: 5584-5594.
55. Guttler T, Madl T, Neumann P, Deichsel D, Corsini L, Monecke T, Ficner R, Sattler M and Gorlich D. NES consensus redefined by structures of PKI-type and Rev-type nuclear export signals bound to CRM1. Nat Struct Mol Biol 2010; 17: 1367-1376.
56. Kutay U and Guttinger S. Leucine-rich nuclearexport signals: born to be weak. Trends Cell Biol 2005; 15: 121-124.
57. Cook A, Bono F, Jinek M and Conti E. Structural biology of nucleocytoplasmic transport. Annu Rev Biochem 2007; 76: 647-671.
58. Engelsma D, Bernad R, Calafat J and Fornerod M. Supraphysiological nuclear export signals bind CRM1 independently of RanGTP and arrest at Nup358. EMBO J 2004; 23: 3643-3652.
59. Waldmann I, Spillner C and Kehlenbach RH. The nucleoporin-like protein NLP1 (hCG1) promotes CRM1-dependent nuclear protein export. J Cell Sci 2012; 125: 144-154.
60. Callanan M, Kudo N, Gout S, Brocard M, Yoshida M, Dimitrov S and Khochbin S. Developmentally regulated activity of CRM1/XPO1 during early Xenopus embryogenesis. J Cell Sci 2000; 113: 451-459.
61. Collier S, Chan HY, Toda T, McKimmie C, Johnson G, Adler PN, O'Kane C and Ashburner M. The Drosophila embargoed gene is required for larval progression and encodes the functional homolog of schizosaccharomyces Crm1. Genetics 2000; 155: 1799-1807.
62. Collier S and Gubb D. Drosophila tissue polarity requires the cell-autonomous activity of the fuzzy gene, which encodes a novel transmembrane protein. Development 1997; 124: 4029-4037.
63. Brinkley BR. Managing the centrosome numbers game: from chaos to stability in cancer cell division. Trends Cell Biol 2001; 11: 18-21.
64. Sluder G and Hinchcliffe EH. Control of centrosome reproduction: the right number at the right time. Biol Cell 1999; 91: 413-427.
65. Wang W, Budhu A, Forgues M and Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 2005; 7: 823-830.
66. Morris SW, Kirstein MN, Valentine MB, Dittmer K, Shapiro DN, Look AT and Saltman DL. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1995; 267: 316-317.
67. Redner RL, Rush EA, Faas S, Rudert WA and Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosminretinoic acid receptor fusion. Blood 1996; 87: 882-886.
68. Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ, Carroll AJ and Morris SW. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemiaOncogene 1996; 12: 265-275.
69. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG and Martelli MF. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266.
70. Narod SA and Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676.
71. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG and Easton DF. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117-1130.
72. Easton DF, Ford D and Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56: 265-271.
73. Deng CX. Roles of BRCA1 in centrosome duplication. Oncogene 2002; 21: 6222-6227.
74. Hsu LC and White RL. BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci USA 1998; 95: 12983-12988.
75. Parvin JD and Sankaran S. The BRCA1 E3 ubiquitin ligase controls centrosome dynamics. Cell Cycle 2006; 5: 1946-1950.
76. Starita LM, Machida Y, Sankaran S, Elias JE, Griffin K, Schlegel BP, Gygi SP and Parvin JD. BRCA1-dependent ubiquitination of gammatubulin regulates centrosome number. Mol Cell Biol 2004; 24: 8457-8466.
77. Brodie KM and Henderson BR. Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome: a role for the nuclear export signal, Crm1, and Aurora A kinase. J Biol Chem 2012; 287: 7701-7716.
78. Fabbro M, Rodriguez JA, Baer R and Henderson BR. BARD1 induces BRCA1 intranuclear foci formation by increasing RING-dependent BRCA1 nuclear import and inhibiting BRCA1 nuclear export. J Biol Chem 2002; 277: 21315-21324.
79. Turner JG, Dawson J and Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol 2012; 83: 1021-1032.
80. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 2006; 18: 609-615.
81. Lens SM, Vader G and Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol 2006; 18: 616-622.
82. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T and Noel JP. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol 2000; 7: 602-608.
83. Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O and Margolis RL. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell 2000; 6: 183-189.
84. Knauer SK, Bier C, Habtemichael N and Stauber RH. The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep 2006; 7: 1259-1265.
85. Rodriguez JA, Span SW, Ferreira CG, Kruyt FA and Giaccone G. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein Survivin. Exp Cell Res 2002; 275: 44-53.
86. Stauber RH, Rabenhorst U, Rekik A, Engels K, Bier C and Knauer SK. Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal. Traffic 2006; 7: 1461-1472.
87. Engelsma D, Rodriguez JA, Fish A, Giaccone G and Fornerod M. Homodimerization antagonizes nuclear export of survivin. Traffic 2007; 8: 1495-1502.
88. Wang H, Holloway MP, Ma L, Cooper ZA, Riolo M, Samkari A, Elenitoba-Johnson KS, Chin YE and Altura RA. Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem 2010; 285: 36129-36137.
89. Riolo MT, Cooper ZA, Holloway MP, Cheng Y, Bianchi C, Eakirevich E, Ma L, Chin YE and Altura RA. HDAC6 deacetylates survivin for its nuclear export in breast cancer. J Biol Chem 2012 Feb 9 [Epub ahead of print].
90. Ruchaud S, Carmena M and Earnshaw WC. The chromosomal passenger complex: one for all and all for one. Cell 2007; 131: 230-231.
91. Vagnarelli P and Earnshaw WC. Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma 2004; 113: 211-222.
92. Klein UR, Nigg EA and Gruneberg U. Centromere targeting of the chromosomal passenger complex requires a ternary subcomplex of Borealin, Survivin, and the N-terminal domain of INCENP. Mol Biol Cell 2006; 17: 2547-2558.
93. Rodriguez JA, Lens SM, Span SW, Vader G, Medema RH, Kruyt FA and Giaccone G. Subcellular localization and nucleocytoplasmic transport of the chromosomal passenger proteins before nuclear envelope breakdown. Oncogene 2006; 25: 4867-4879.
94. Rannou Y, Troadec MB, Petretti C, Hans F, Dutertre S, Dimitrov S and Prigent C. Localization of aurora A and aurora B kinases during interphase: role of the N-terminal domain. Cell Cycle 2008; 7: 3012-3020.
95. Kelly RJ, Lopez-Chavez A, Citrin D, Janik JE and Morris JC. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cancer 2011; 10: 35.
96. Altieri DC. Survivin and IAP proteins in celldeath mechanisms. Biochem J 2010; 430: 199-205.
97. DC. Survivin, cancer networks and pathway- directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
98. Li F, Yang J, Ramnath N, Javle MM and Tan D. Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005; 114: 509-512.
99. Knauer SK, Kramer OH, Knosel T, Engels K, Rodel F, Kovacs AF, Dietmaier W, Klein-Hitpass L, Habtemichael N, Schweitzer A, Brieger J, Rodel C, Mann W, Petersen I, Heinzel T and Stauber RH. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 2007; 21: 207-216.
100. Chan KS, Wong CH, Huang YF and Li HY. Survivin withdrawal by nuclear export failure as a physiological switch to commit cells to apoptosis. Cell Death Dis 2010; 1: e57.
101. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE and Gerharz CD. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002; 9: 1334-1342.
102. Sampath J and Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol 2007; 4: 174-191.
103. Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rodel F, Klein-Hitpass L, Kovacs AF, Doring C, Hansmann ML, Hofmann WK, Kunkel M, Brochhausen C, Engels K, Lippert BM, Mann W and Stauber RH. The survivin isoform survivin- 3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle 2007; 6: 1502-1509.
104. Hengst L, Dulic V, Slingerland JM, Lees E and Reed SI. A cell cycle-regulated inhibitor of cyclin -dependent kinases. Proc Natl Acad Sci USA 1994; 91: 5291-5295.
105. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P and Massague J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
106. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR and Reed SI. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell Biol 1994; 14: 3683-3694.
107. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM and Sherr CJ. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 1999; 18: 1571-1583.
108. Slingerland J and Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183: 10-17.
109. Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H and Koff A. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 1997; 272: 7093-7098.
110. Connor MK, Kotchetkov R, Cariou S, Resch A, Lupetti R, Beniston RG, Melchior F, Hengst L and Slingerland JM. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 2003; 14: 201-213.
111. Rodier G, Montagnoli A, Di Marcotullio L, Coulombe P, Draetta GF, Pagano M and Meloche S. p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis. EMBO J 2001; 20: 6672-6682.
112. Boehm M, Yoshimoto T, Crook MF, Nallamshetty S, True A, Nabel GJ and Nabel EG. A growth factor-dependent nuclear kinase phosphorylates p27(Kip1) and regulates cell cycle progression. EMBO J 2002; 21: 3390-3401.
113. Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K and Nakayama KI. Phosphorylation of p27Kip1 on serine 10 is required for its binding to CRM1 and nuclear export. J Biol Chem 2002; 277: 14355-14358.
114. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA and Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996; 85: 721-732.
115. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I and Loh DY. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85: 707-720.
116. Larrea MD, Wander SA and Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle 2009; 8: 3455-3461.
117. Wander SA, Zhao D and Slingerland JM. p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res 2011; 17: 12-18.
118. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava- Protzner I, Kapusta L, Franssen E, Pritchard KI and Slingerland JM. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227-230.
119. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M and Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997; 57: 1259-1263.
120. Nohara T, Ryo T, Iwamoto S, Gon G and Tanigawa N. Expression of cell-cycle regulator p27 is correlated to the prognosis and ER expression in breast carcinoma patients. Oncology 2001; 60: 94-100.
121. Aylon Y and Oren M. p53: guardian of ploidy. Mol Oncol 2011; 5: 315-323.
122. Bieging KT and Attardi LD. Deconstructing p53 transcriptional networks in tumor suppression. Trends Cell Biol 2012; 22: 97-106.
123. Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Adv Cancer Res 2011; 110: 107-139.
124. Cai X and Liu X. Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc Natl Acad Sci USA 2008; 105: 16958-16963.
125. Freedman DA and Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998; 18: 7288-7293.
126. van der Watt PJ and Leaner VD. The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA damage. Biochim Biophys Acta 2011; 1809: 316-326.
127. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ and Wahl GM. A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999; 18: 1660-1672.
128. Zhang Y and Xiong Y. A p53 amino-terminal nuclear export signal inhibited by DNA damageinduced phosphorylation. Science 2001; 292: 1910-1915.
129. Lohrum MA, Woods DB, Ludwig RL, Balint E and Vousden KH. C-terminal ubiquitination of p53 contributes to nuclear export. Mol Cell Biol 2001; 21: 8521-8532.
130. Nie L, Sasaki M and Maki CG. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem 2007; 282: 14616-14625.
131. Stewart D, Ghosh A and Matlashewski G. Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53. J Virol 2005; 79: 8773-8783.
132. Bienz M and Clevers H. Linking colorectal cancer to Wnt signaling. Cell 2000; 103: 311-320.
133. Burgess AW, Faux MC, Layton MJ and Ramsay RG. Wnt signaling and colon tumorigenesis--a view from the periphery. Exp Cell Res 2011; 317: 2748-2758.
134. Minde DP, Anvarian Z, Rudiger SG and Maurice MM. Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer? Mol Cancer 2011; 10: 101.
135. Benchabane H and Ahmed Y. The adenomatous polyposis coli tumor suppressor and Wnt signaling in the regulation of apoptosis. Adv Exp Med Biol 2009; 656: 75-84.
136. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14: 1837-1851.
137. Neufeld KL, Nix DA, Bogerd H, Kang Y, Beckerle MC, Cullen BR and White RL. Adenomatous polyposis coli protein contains two nuclear export signals and shuttles between the nucleus and cytoplasm. Proc Natl Acad Sci USA 2000; 97: 12085-12090.
138. Henderson BR and Fagotto F. The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep 2002; 3: 834-839.
139. Eleftheriou A, Yoshida M and Henderson BR. Nuclear export of human beta-catenin can occur independent of CRM1 and the adenomatous polyposis coli tumor suppressor. J Biol Chem 2001; 276: 25883-25888.
140. Tickenbrock L, Cramer J, Vetter IR and Muller O. The coiled coil region (amino acids 129-250) of the tumor suppressor protein adenomatous polyposis coli (APC). Its structure and its interaction with chromosome maintenance region 1 (Crm-1). J Biol Chem 2002; 277: 32332-32338.
141. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat Cell Biol 2000; 2: 653-660.
142. Sansom O. Tissue-specific tumour suppression by APC. Adv Exp Med Biol 2009; 656: 107-118.
143. Anderson CB, Neufeld KL and White RL. Subcellular distribution of Wnt pathway proteins in normal and neoplastic colon. Proc Natl Acad Sci USA 2002; 99: 8683-8688.
144. Hamamoto T, Gunji S, Tsuji H and Beppu T. Leptomycins A and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterization. J Antibiot (Tokyo) 1983; 36: 639-645.
145. Yoshida M, Nishikawa M, Nishi K, Abe K, Horinouchi S and Beppu T. Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cells. Exp Cell Res 1990; 187: 150-156.
146. Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M and Horinouchi S. Leptomycin B inactivates CRM1/ exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999; 96: 9112-9117.
147. London CA, Barnard S, Kisseberth W, Plamondon L, Shacham S and Kauffman M. Preliminary results of a phase I study of the novel CRM1 inhibitors KPT-276 and KPT-335 in dogs with spontaneous cancer. Blood (abstract) 2012.
148. Landesman Y, Senapedis W, Sanint-Martin J-R, Kashyap T, Plamondon L, Sandanayaka V, Shechter S, Froim D, McCauley D, Kauffman M and Shacham S. Pharmacokinetic (PK)/ pharmacodynamic (PD) and efficacy relationship of selective inhibitors of nuclear export (KPT-SINE) Blood (abstract) 2012.
149. Thompson JD, Higgins DG and Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-4680.
150. Simossis VA and Heringa J. PRALINE: a multiple sequence alignment toolbox that integrates homology-extended and secondary structure information. Nucleic Acids Res 2005; 33: W289-294.